Auxilium Pharmaceuticals’ total revenues decrease 17% to $83 million in Q2 2014
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.